{"protocolSection": {"identificationModule": {"nctId": "NCT00087516", "orgStudyIdInfo": {"id": "0431-021"}, "secondaryIdInfos": [{"id": "Formally-C0604MT2D"}, {"id": "MK0431-021"}, {"id": "2006_413"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)", "officialTitle": "A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2015-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-06"}, "primaryCompletionDateStruct": {"date": "2005-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2004-07-09", "studyFirstSubmitQcDate": "2004-07-12", "studyFirstPostDateStruct": {"date": "2004-07-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-10", "resultsFirstSubmitQcDate": "2010-05-10", "resultsFirstPostDateStruct": {"date": "2010-06-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-06-08", "lastUpdatePostDateStruct": {"date": "2015-07-03", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 741, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin 100 mg/100 mg", "type": "ACTIVE_COMPARATOR", "description": "Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )", "interventionNames": ["Drug: Sitagliptin (MK0431)", "Drug: Metformin - Rescue"]}, {"label": "Sitagliptin 200 mg/200 mg", "type": "ACTIVE_COMPARATOR", "description": "Phase A and B: Oral tablets of sitagliptin 200 mg q.d", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin - Rescue"]}, {"label": "Placebo/Sitagliptin 100 mg", "type": "PLACEBO_COMPARATOR", "description": "Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.", "interventionNames": ["Drug: Placebo", "Drug: Metformin - Rescue"]}, {"label": "Placebo/Sitagliptin 200 mg", "type": "PLACEBO_COMPARATOR", "description": "Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.", "interventionNames": ["Drug: Placebo", "Drug: Metformin - Rescue"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin (MK0431)", "description": "Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.", "armGroupLabels": ["Sitagliptin 100 mg/100 mg"], "otherNames": ["MK0431", "Januvia"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.", "armGroupLabels": ["Sitagliptin 200 mg/200 mg"], "otherNames": ["MK0431", "Januvia"]}, {"type": "DRUG", "name": "Placebo", "description": "Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.", "armGroupLabels": ["Placebo/Sitagliptin 100 mg"]}, {"type": "DRUG", "name": "Placebo", "description": "Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.", "armGroupLabels": ["Placebo/Sitagliptin 200 mg"]}, {"type": "DRUG", "name": "Metformin - Rescue", "description": "Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.", "armGroupLabels": ["Placebo/Sitagliptin 100 mg", "Placebo/Sitagliptin 200 mg", "Sitagliptin 100 mg/100 mg", "Sitagliptin 200 mg/200 mg"], "otherNames": ["Metformin", "Glucophage", "Glucophage XR", "Glumetza", "Fortamet", "Riomet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 24", "description": "A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Weeks 0-24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FPG at Week 24", "description": "Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG.", "timeFrame": "Weeks 0-24"}, {"measure": "Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24", "description": "Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG.", "timeFrame": "Weeks 0-24"}, {"measure": "Change From Baseline in A1C at Week 104", "description": "A1C is measured as a percent. Thus, this change from baseline reflects the Week 104 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Weeks 0-104"}, {"measure": "Change From Baseline in FPG at Week 104", "description": "Change from baseline at Week 104 is defined as Week 104 FPG minus Week 0 FPG.", "timeFrame": "Weeks 0-104"}, {"measure": "Change From Baseline in 2-hr PMG at Week 104", "description": "Change from baseline at Week 104 is defined as Week 104 2-hr PMG minus Week 0 2-hr PMG.", "timeFrame": "Weeks 0-104"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus\n* Patient is not pregnant or breastfeeding\n* Male or female patient unlikely to conceive\n* Patient not on an antihyperglycemic drug\n\nExclusion Criteria:\n\n* Patient has history of type 1 diabetes mellitus\n* Patient has history of ketoacidosis\n* Patient requires insulin within 8 weeks prior to start of study\n* Patient on weight loss program and is not in maintenance phase\n* Patient taking weight loss medication within 8 weeks prior to start of study\n* Patient on or likely to require = 14 days or repeated courses of corticosteroids\n* Patient taking immunosuppressive/immunomodulating medication\n* Patient taking digoxin or other cardiac medication\n* Patient has undergone surgical general anesthesia within 30 days prior to start of study\n* Patient taking investigational drug within 8 weeks prior to start of study\n* Patient is diagnosed with liver disease\n* Patient has chronic myopathy, progressive neurological/neuromuscular disorder\n* Patient has with severe cardiac conditions within the last 6 months\n* Patient is Human immunodeficiency virus (HIV) positive\n* Patient has hematological disorder\n* Patient has history of malignancy\n* Patient has history of alcohol or drug abuse within the past 3 years", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "17130196", "type": "BACKGROUND", "citation": "Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-75 years not on an antihyperglycemic agent (AHA) or on oral single AHA or low-dose combination therapy were eligible to participate. Following a screening diet/exercise period of variable duration, patients with hemoglobin A1c (A1C) 7-10% were eligible to enter a 2-week placebo run-in/wash-off period prior to randomization.", "recruitmentDetails": "First Patient In: 08-Jul-2004; Last Patient Last Visit: 07-Feb-2007; One hundred eleven medical clinics worldwide (56 in the United States and Puerto Rico, 16 in 6 countries in Europe and 39 in 11 countries in the rest of the world).", "groups": [{"id": "FG000", "title": "Sitagliptin 100 mg/100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "FG001", "title": "Sitagliptin 200 mg/200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "FG002", "title": "Placebo/Sitagliptin 100 mg", "description": "The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period."}, {"id": "FG003", "title": "Placebo/Sitagliptin 200 mg", "description": "The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "238"}, {"groupId": "FG001", "numSubjects": "250"}, {"groupId": "FG002", "numSubjects": "130"}, {"groupId": "FG003", "numSubjects": "123"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "81"}, {"groupId": "FG002", "numSubjects": "33"}, {"groupId": "FG003", "numSubjects": "38"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "161"}, {"groupId": "FG001", "numSubjects": "169"}, {"groupId": "FG002", "numSubjects": "97"}, {"groupId": "FG003", "numSubjects": "85"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "82"}, {"groupId": "FG001", "numSubjects": "80"}, {"groupId": "FG002", "numSubjects": "39"}, {"groupId": "FG003", "numSubjects": "29"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "12"}]}, {"type": "Site terminated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol specified discontinuation", "reasons": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "33"}, {"groupId": "FG002", "numSubjects": "33"}, {"groupId": "FG003", "numSubjects": "26"}]}, {"type": "Patient moved", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Patient was non-compliant", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Recommendation of Primary Care Physician", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "BG001", "title": "Sitagliptin 200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "BG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "238"}, {"groupId": "BG001", "value": "250"}, {"groupId": "BG002", "value": "253"}, {"groupId": "BG003", "value": "741"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.4", "spread": "9.5"}, {"groupId": "BG001", "value": "54.9", "spread": "10.1"}, {"groupId": "BG002", "value": "54.3", "spread": "10.1"}, {"groupId": "BG003", "value": "54.2", "spread": "9.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "123"}, {"groupId": "BG003", "value": "358"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "130"}, {"groupId": "BG003", "value": "383"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "132"}, {"groupId": "BG002", "value": "127"}, {"groupId": "BG003", "value": "381"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "38"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "64"}, {"groupId": "BG003", "value": "175"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "34"}, {"groupId": "BG003", "value": "103"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "44"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.7", "spread": "43.0"}, {"groupId": "BG001", "value": "174.2", "spread": "46.2"}, {"groupId": "BG002", "value": "176.1", "spread": "41.8"}, {"groupId": "BG003", "value": "173.7", "spread": "43.7"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.0", "spread": "0.9"}, {"groupId": "BG001", "value": "8.1", "spread": "0.9"}, {"groupId": "BG002", "value": "8.0", "spread": "0.8"}, {"groupId": "BG003", "value": "8.0", "spread": "0.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 24", "description": "A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Weeks 0-24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG001", "title": "Sitagliptin 200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "229"}, {"groupId": "OG001", "value": "238"}, {"groupId": "OG002", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.61", "lowerLimit": "-0.74", "upperLimit": "-0.49"}, {"groupId": "OG001", "value": "-0.76", "lowerLimit": "-0.88", "upperLimit": "-0.64"}, {"groupId": "OG002", "value": "0.18", "lowerLimit": "0.06", "upperLimit": "0.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline A1C", "paramType": "Mean Difference (Net)", "paramValue": "-0.79", "ciPctValue": "95", "ciLowerLimit": "-0.96", "ciUpperLimit": "-0.62", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.09"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline A1C", "paramType": "Mean Difference (Net)", "paramValue": "-0.94", "ciPctValue": "95", "ciLowerLimit": "-1.11", "ciUpperLimit": "-0.77", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.09"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 24", "description": "Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG.", "populationDescription": "The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Weeks 0-24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG001", "title": "Sitagliptin 200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "234"}, {"groupId": "OG001", "value": "244"}, {"groupId": "OG002", "value": "247"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.4", "lowerLimit": "-17.4", "upperLimit": "-7.4"}, {"groupId": "OG001", "value": "-16.6", "lowerLimit": "-21.5", "upperLimit": "-11.7"}, {"groupId": "OG002", "value": "4.7", "lowerLimit": "-0.2", "upperLimit": "9.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline FPG", "paramType": "Mean Difference (Net)", "paramValue": "-17.1", "ciPctValue": "95", "ciLowerLimit": "-24.1", "ciUpperLimit": "-10.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.6"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline FPG", "paramType": "Mean Difference (Net)", "paramValue": "-21.3", "ciPctValue": "95", "ciLowerLimit": "-28.2", "ciUpperLimit": "-14.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24", "description": "Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG.", "populationDescription": "The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Weeks 0-24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG001", "title": "Sitagliptin 200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "201"}, {"groupId": "OG001", "value": "205"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-48.9", "lowerLimit": "-57.9", "upperLimit": "-40.0"}, {"groupId": "OG001", "value": "-56.3", "lowerLimit": "-65.2", "upperLimit": "-47.5"}, {"groupId": "OG002", "value": "-2.2", "lowerLimit": "-11.1", "upperLimit": "6.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline 2-hr PMG", "paramType": "Mean Difference (Net)", "paramValue": "-46.7", "ciPctValue": "95", "ciLowerLimit": "-59.4", "ciUpperLimit": "-34.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.5"}, {"groupIds": ["OG001", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline 2-hr PMG", "paramType": "Mean Difference (Net)", "paramValue": "-54.1", "ciPctValue": "95", "ciLowerLimit": "-66.7", "ciUpperLimit": "-41.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 104", "description": "A1C is measured as a percent. Thus, this change from baseline reflects the Week 104 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The all-patients-treated population for Week 104 included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Weeks 0-104", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg/100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG001", "title": "Sitagliptin 200 mg/200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG002", "title": "Placebo/ Sitagliptin 100 mg", "description": "The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period."}, {"id": "OG003", "title": "Placebo/Sitagliptin 200 mg", "description": "The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "188"}, {"groupId": "OG001", "value": "195"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.27", "lowerLimit": "-0.41", "upperLimit": "-0.13"}, {"groupId": "OG001", "value": "-0.40", "lowerLimit": "-0.53", "upperLimit": "-0.26"}, {"groupId": "OG002", "value": "-0.32", "lowerLimit": "-0.53", "upperLimit": "-0.11"}, {"groupId": "OG003", "value": "-0.34", "lowerLimit": "-0.55", "upperLimit": "-0.13"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 104", "description": "Change from baseline at Week 104 is defined as Week 104 FPG minus Week 0 FPG.", "populationDescription": "The all-patients-treated population for Week 104, included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Weeks 0-104", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg/100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG001", "title": "Sitagliptin 200 mg/200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG002", "title": "Placebo/Sitagliptin 100 mg", "description": "The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period."}, {"id": "OG003", "title": "Placebo/Sitagliptin 200 mg", "description": "The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "81"}, {"groupId": "OG003", "value": "83"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "lowerLimit": "-7.3", "upperLimit": "3.7"}, {"groupId": "OG001", "value": "-5.7", "lowerLimit": "-11.1", "upperLimit": "-0.2"}, {"groupId": "OG002", "value": "-4.1", "lowerLimit": "-12.5", "upperLimit": "4.3"}, {"groupId": "OG003", "value": "-4.1", "lowerLimit": "-12.4", "upperLimit": "4.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hr PMG at Week 104", "description": "Change from baseline at Week 104 is defined as Week 104 2-hr PMG minus Week 0 2-hr PMG.", "populationDescription": "The all-patients-treated population for Week 104, included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Weeks 0-104", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg/100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG001", "title": "Sitagliptin 200 mg/200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period)."}, {"id": "OG002", "title": "Placebo/Sitagliptin 100 mg", "description": "The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period."}, {"id": "OG003", "title": "Placebo/Sitagliptin 200 mg", "description": "The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "165"}, {"groupId": "OG001", "value": "168"}, {"groupId": "OG002", "value": "68"}, {"groupId": "OG003", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-30.5", "lowerLimit": "-40.1", "upperLimit": "-21.0"}, {"groupId": "OG001", "value": "-41.5", "lowerLimit": "-51.0", "upperLimit": "-32.1"}, {"groupId": "OG002", "value": "-38.3", "lowerLimit": "-53.2", "upperLimit": "-23.4"}, {"groupId": "OG003", "value": "-35.5", "lowerLimit": "-50.9", "upperLimit": "-20.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Weeks 0-104", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 100 mg/100 mg", "description": "The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).", "seriousNumAffected": 24, "seriousNumAtRisk": 238, "otherNumAffected": 127, "otherNumAtRisk": 238}, {"id": "EG001", "title": "Sitagliptin 200 mg/200 mg", "description": "The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).", "seriousNumAffected": 25, "seriousNumAtRisk": 250, "otherNumAffected": 137, "otherNumAtRisk": 250}, {"id": "EG002", "title": "Placebo/Sitagliptin 100 mg", "description": "The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period.", "seriousNumAffected": 10, "seriousNumAtRisk": 130, "otherNumAffected": 70, "otherNumAtRisk": 130}, {"id": "EG003", "title": "Placebo/Sitagliptin 200 mg", "description": "The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period.", "seriousNumAffected": 13, "seriousNumAtRisk": 123, "otherNumAffected": 65, "otherNumAtRisk": 123}], "seriousEvents": [{"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 123}]}, {"term": "Myocardial Ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Borderline Glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Abdominal Strangulated Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Gallbladder Necrosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Sarcoidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 123}]}, {"term": "Abscess Of Salivary Gland", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Bronchitis Acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Lobar Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Pneumonia Legionella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Staphylococcal Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Staphylococcal Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Urethritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Anaesthetic Complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Ankle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Foreign Body Trauma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Lung Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Radial Nerve Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Road Traffic Accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Skin Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Hepatic Enzyme Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Lipase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cervical Spinal Stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Adrenal Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Basal Cell Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 123}]}, {"term": "Benign Renal Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Colon Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Hepatic Neoplasm Malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Lung Adenocarcinoma Stage IV", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Mesothelioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Prostate Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Rectal Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Rectal Cancer Metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Renal Cell Carcinoma Stage Unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Lacunar Infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Suicidal Behavior", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Suicidal Ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Vaginal Cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 123}]}, {"term": "Deep Vein Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 123}]}], "otherEvents": [{"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 123}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 123}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 123}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 123}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 123}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 123}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 123}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 123}]}, {"term": "Blood Glucose Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 123}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 123}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 123}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 123}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 123}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 238}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 250}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 130}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 123}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Puerto Rico", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}